Pure Global AI
NCT06136936Recruiting

A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

A Multicenter, Exploratory, Randomized, Double-Arm, 4-week Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia
Click Therapeutics, Inc.ClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Schizophrenia
Drug/Device/Intervention
CT-156-C-001
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Click Therapeutics, Inc.
Location
New York, United States of America
Timeline & enrollment
Phase
N/A
Start date
Sep 20, 2023
End date
Mar 14, 2024
Enrollment
50 participants
Primary outcome

Number of days used,Number of times Study App is opened,Number of tasks completed,Length of time in App

Summary

An exploratory, double-arm, 4-week study to explore the feasibility and acceptability of
 abbreviated treatment with CT-156 for people with Schizophrenia.

ICD-10 classifications
SchizophreniaSimple schizophreniaSchizophrenia, unspecifiedOther schizophreniaParanoid schizophrenia
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06136936
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06136936 through Pure Global AI's free database. This phase not specified trial is sponsored by Click Therapeutics, Inc. and is currently Recruiting. The study focuses on Schizophrenia. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.